The trial is enrolling in the US and will include regions in the Asia Pacific, Europe, Latin America, and North America.

On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...

On a bad day for the stock market overall, Deciphera Pharmaceuticals (NASDAQ: DCPH) was quite the happy standout. Shares of the biotech closed more than 12% higher on Tuesday thanks to the launch of a ...

Ono Pharmaceutical has agreed to buy cancer drugmaker Deciphera Pharmaceuticals in a deal that values the latter company at $2.4 billion. Per deal terms, Ono is purchasing in cash all outstanding ...

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has recently experienced a daily loss of 2.19% and a 3-month loss of 10.22%. The company's Earnings Per Share (EPS) (EPS) also indicate a loss of 2.32.

Deciphera Pharmaceuticals (NASDAQ:DCPH) has observed the following analyst ratings within the last quarter: According to 8 analyst offering 12-month price targets in the last 3 months, Deciphera ...

Deciphera Pharmaceuticals (NASDAQ:DCPH) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical (OTCMKTS:OPHLY). This deal has ONO acquiring ...

WALTHAM, Mass.-- (BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today ...

Deciphera Pharmaceuticals (NASDAQ:DCPH) stock absolutely imploded in November. Shares lost more than two-thirds of their value virtually overnight. In November, Deciphera presented its clinical ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022. In connection ...